Treatment of bone metastases of prostate cancer with strontium-89 chloride:: efficacy in relation to the degree of bone involvement
Treatment of bone metastases of prostate cancer with strontium-89 chloride:: efficacy in relation to the degree of bone involvement
复制标题
DOI：
10.1007/s002590000315
复制
发表时间：
2000-10-01
期刊：
影响因子：
--
通讯作者：
Resche, I
中科院分区：
文献类型：
--
作者：
Kraeber-Bodéré, F;Campion, L;Resche, I
这项回顾性研究评价了氯化锶-89（Metastron，阿默舍姆）在94例前列腺癌疼痛性骨转移患者（117次注射150 MBq）中的毒性和疗效，并比较了中度和广泛骨受累患者的治疗疗效。还研究了耀斑反应对镇痛反应的预测价值，仅在5%的注射后观察到高度白血球减少。65%的病例生活质量得到改善，78%的病例疼痛减轻（31%完全缓解），60%的病例镇痛药减少。疼痛减轻（P=0.005）和镇痛药用量减少（P=0.018）的疗效明显优于对照组，反应时间明显延长（P
This retrospective study evaluated the toxicity and efficacy of strontium-89 chloride (Metastron, Amersham) in 94 patients with painful bone metastases of prostate cancer (117 injections of 150 MBq) and compared the efficacy of treatment in patients with moderate and extensive bone involvement. The predictive value of flare response with regard to analgesic response was also studied, High-grade leukothrombopenias were observed after only 5% of injections. An improvement in quality of life was obtained in 65% of cases, a decrease in pain in 78% (31% complete response) and a reduction of analgesics in 60%. Efficacy was significantly better for pain decrease (P=0.005) and reduction of analgesics (P=0.018), and response was significantly longer (P